ClinicalTrials.gg
Active, not recruitingNCT06640257Updated Aug 6, 2026

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

A Phase 3 interventional study of SHR-1314 injection and Placebo in Psoriatic Arthritis, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic with a site in China — 10 open to participants now, 19 under way, 11 of them phase 3. Arthritis, Psoriatic · China.

Enrollment
14th of 27
208 · median 208
Started
2024
with 3 others
Phase 3
14 of 34
2 open now
Primary completion
2026-06
later than 6 of 18 live
Registered
20th of 34
by date
Lead sponsor
2 of 34
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 34 studies in Arthritis, Psoriatic with a site in China, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 6 of the 18 other live ones, and was the 20th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

10 of the 34 studies in Arthritis, Psoriatic with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily signs an form before any procedures related to the research start;
  2. At the time of screening, it met the 2006 psoriatic arthritis classification standard (CASPAR);
  3. There is active PsA before randomization;
  4. Have active plaque psoriasis (at least one plaque skin lesion) at the time of screening, or have a history of plaque psoriasis;
  5. Participants who have previously been treated with csDMARDs and/or NSAIDs still have active psoriatic arthritis disease.

Exclusion criteria

Exclusion Criteria:

  1. Existence of any of the following medical history or comorbid diseases: drug-induced psoriasis; other active inflammatory diseases or diseases; history of organ transplantation; history of lymphocytic proliferation; severe infections, etc.
  2. Have received psoriatic arthritis or psoriasis drugs, such as intra-articular injections, plant preparations, etc. within a certain period of time in the past.
  3. Those who are allergic to the drug ingredients or in this study, or are allergic to other biological agents.
  4. A history of alcohol abuse or illegal drug abuse in pregnant or breastfeeding women, etc.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    SHR-1314 injection

    Drug: SHR-1314 injection

  • Placebo comparator
    placebo

    Drug: SHR-1314 injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving ACR 20 improvement at week 24

    Time frame: Week 24

Secondary outcomes

  1. The proportion of subjects who achieved ACR 50 improvement

    Time frame: Week 24

  2. The proportion of subjects who achieved ACR 70 improvement

    Time frame: Week 24

07

Study locations

1 site
  • Huashan Hospital of the Shanghai FuDan University
    Shanghai, Shanghai Municipality 200433, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jun 2026, 19 months.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 15, 2024
StartActual
Nov 4, 2024
Primary completionActual
Jun 5, 2026
CompletionEst.
Jan 30, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06640257
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 4, 2024
Primary completion
Jun 5, 2026
Completion
Jan 30, 2027 (estimated)
Last update
Aug 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion